Isaac Barchas
CIK: 0001808343
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
TMC shares hit 52-week lows as CEO dismisses selloff. TMC the metals company shares recently reached fresh 52-week lows, prompting the CEO to state that the decline is not fundamental. The executive noted that market negativity can sometimes feed on itself, suggesting the drop may be driven by sentiment rather than business changes. This context is relevant as the stock trades near its 52-week low of $3.31, well below the average analyst target of $10.90.
Transaction History
| IMNM | ▼ Sell | Open Market | 11,048 | $301K | 8/12/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 62,291 | $1.6M | 8/11/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 10,125 | $264K | 8/10/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 15,248 | $397K | 8/7/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 20,840 | $543K | 8/6/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 16,906 | $409K | 7/7/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 83,094 | $2.0M | 7/6/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 75,665 | $1.7M | 7/2/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 24,335 | $568K | 7/2/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 101,050 | $2.1M | 6/30/2026 | View on chart |
| IMNM | ▼ Sell | Open Market | 371,949 | $8.1M | 12/22/2025 | View on chart |
| IMNM | ▼ Sell | Open Market | 11,251 | $251K | 12/22/2025 | View on chart |
| TMC | ▲ Buy | Option Exercise | 30,000 | — | 9/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Immunome files Nasdaq inducement grant report, sees higher volume
Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.
Immunome files Nasdaq inducement grant report, sees higher volume. Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.